Helicobacter pylori: Clinical management

Current Opinion in Gastroenterology

Volumn 28, Issue 6, 2012, Pages 608-614

  Malfertheiner, Peter ^a   Selgrad, Michael ^a   Bornschein, Jan ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

eradication therapy; extragastric diseases; gastric cancer prevention; gastroduodenal pathologies; Helicobacter pylori

Indexed keywords

CLARITHROMYCIN; HEMOGLOBIN A1C; LEVOFLOXACIN; PEPSINOGEN I; PEPSINOGEN II; PROBIOTIC AGENT; PROTON PUMP INHIBITOR;

ALGORITHM; ALZHEIMER DISEASE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BIFIDOBACTERIUM; CANCER PREVENTION; COLON CANCER; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DRUG EFFICACY; ENZYME BLOOD LEVEL; ERADICATION THERAPY; HELICOBACTER INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; IRON DEFICIENCY ANEMIA; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; OBESITY; PEPTIC ULCER; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHAROMYCES BOULARDII; SEROLOGY; STOMACH CANCER; TREATMENT DURATION; TREATMENT INDICATION; YEAST;

ANTI-BACTERIAL AGENTS; COLONIC NEOPLASMS; DRUG RESISTANCE, BACTERIAL; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NEURODEGENERATIVE DISEASES; PEPTIC ULCER; PROBIOTICS; STOMACH NEOPLASMS;

EID: 84868375644     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835918a7     Document Type: Review

References (158)

1. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010; 15 (Suppl 1):1-6.
2. Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol 2012; 175:54-59.
3. McNulty CA, Lasseter G, Shaw I, et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 2012; 35:1221-1230.
4. Wex T, Venerito M, Kreutzer J, et al. Serological prevalence of Helicobacter pylori infection in Saxony-Anhalt, Germany, in 2010. Clin Vaccine Immunol 2011; 18:2109-2112.
5. Pandeya N, Whiteman DC. Prevalence and determinants of Helicobacter pylori sero-positivity in the Australian adult community. J Gastroenterol Hepatol 2011; 26:1283-1289.
6. Miendje D, Vanderpas J, Bontems P, et al. Marching cohort of Helicobacter pylori infection over two decades (1988-2007): combined effects of secular trend and population migration. Epidemiol Infect 2011; 139:572-580.
7. Smith SM, Moran AP, Duggan SP, et al. Tribbles 3: a novel regulator of TLR2-mediated signaling in response to Helicobacter pylori lipopolysaccharide. J Immunol 2011; 186:2462-2471.
8. Kumar PS, Brandt S, Madassery J, Backert S. Induction of TLR-2 and TLR-5 expression by Helicobacter pylori switches cagPAI-dependent signalling leading to the secretion of IL-8 and TNF-alpha. PLoS One 2011; 6:e19614.
9. Arnold IC, Dehzad N, Reuter S, et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 2011; 121:3088-3093.
10. Suzuki R, Shiota S, Yamaoka Y. Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori. Infect Genet Evol 2012; 12:203-213.
11. Rolig AS, Carter JE, Ottemann KM. Bacterial chemotaxis modulates host cell apoptosis to establish a T-helper cell, type 17 (Th17)-dominant immune response in Helicobacter pylori infection. Proc Natl Acad Sci U S A 2011; 108:19749-19754.
12. Katicic M, Filipec KT, Mrzljak A, et al. The decline in prevalence of H. pylori infection in Croatia affect significantly in incidence of esofago-gastro-duodenal (EGD) endoscopic findings. Helicobacter 2011; 16:105.
13. Zelickson MS, Bronder CM, Johnson BL, et al. Helicobacter pylori is not the predominant etiology for peptic ulcers requiring operation. Am Surg 2011; 77:1054-1060.
14. Kang JM, Kim N, Lee BH, et al. Risk factors for peptic ulcer bleeding in terms of Helicobacter pylori, NSAIDs, and antiplatelet agents. Scand J Gastroenterol 2011; 46:1295-1301.
15. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012; 61:646-664.
16. Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol 2012; 27:626-641.
17. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011; 171: 1929-1936.
18. Lan L, Yu J, Chen YL, et al. Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol 2011; 17:3242-3247.
19. Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol 2012; 47:129-135.
20. Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2011; 16 (Suppl 1):65-69.
21. Figura N, Franceschi F, Santucci A, et al. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010; 15 (Suppl 1):60-68.
22. Nweneka CV, Prentice AM. Helicobacter pylori infection and circulating ghrelin levels: a systematic review. BMC Gastroenterol 2011; 11:7.
23. Weigt J, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake. Curr Opin Clin Nutr Metab Care 2009; 12:522-525.
24. Akanuma M, Yanai A, Sakamoto K, et al. Influence of Helicobacter pylori eradication on the management of type 2 diabetes. Hepatogastroenterology 2012; 59:10.
25. Georges JL, Rupprecht HJ, Blankenberg S, et al. Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines. Am J Cardiol 2003; 92:515-521.
26. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115:1111-1119.
27. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010; 31:817-844.
28. Jeon CY, Haan MN, Cheng C, et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012; 35:520-525.
29. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the bloodbrain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003; 34:806-812.
30. Deretzi G, Kountouras J, Polyzos SA, et al. Gastrointestinal immune system and brain dialogue implicated in neuroinflammatory and neurodegenerative diseases. Curr Mol Med 2011; 11:696-707.
31. Mecocci P, Parnetti L, Reboldi GP, et al. Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias. Acta Neurol Scand 1991; 84:210-213.
32. Roubaud-Baudron C, Krolak-Salmon P, Quadrio I, et al. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiol Aging 2012; 33:1009.
33. Malaguarnera M, Ferri R, Bella R, et al. Homocysteine, vitamin B12 and folate in vascular dementia and in Alzheimer disease. Clin Chem Lab Med 2004; 42:1032-1035.
34. Kountouras J, Tsolaki M, Gavalas E, et al. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology 2006; 66:938-940.
35. Kountouras J, Boziki M, Gavalas E, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol 2009; 256:758-767.
36. Malaguarnera M, Bella R, Alagona G, et al. Helicobacter pylori and Alzheimer's disease: a possible link. Eur J Intern Med 2004; 15:381-386.
37. Shiota S, Murakami K, Yoshiiwa A, et al. The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. J Neurol 2011; 258:1460-1463.
38. Meucci G, Tatarella M, Vecchi M, et al. High prevalence of Helicobacter pylori infection in patients with colonic adenomas and carcinomas. J Clin Gastroenterol 1997; 25:605-607.
39. Shmuely H, Passaro D, Figer A, et al. Relationship between Helicobacter pylori CagA status and colorectal cancer. Am J Gastroenterol 2001; 96:3406-3410.
40. Siddheshwar RK, Muhammad KB, Gray JC, Kelly SB. Seroprevalence of Helicobacter pylori in patients with colorectal polyps and colorectal carcinoma. Am J Gastroenterol 2001; 96:84-88.
41. Konturek PC, Konturek SJ, Bielanski W, et al. Role of gastrin in gastric cancerogenesis in Helicobacter pylori infected humans. J Physiol Pharmacol 1999; 50:857-873.
42. Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastrin: active participant or bystander in gastric carcinogenesis? Nat Rev Cancer 2006; 6:936-946.
43. Niv Y. Gastrin and colorectal neoplasia: cause and effect. Digestion 2006; 74:40-41.
44. Zumkeller N, Brenner H, Zwahlen M, Rothenbacher D. Helicobacter pylori infection and colorectal cancer risk: a meta-analysis. Helicobacter 2006; 11:75-80.
45. Zhao YS, Wang F, Chang D, et al. Meta-analysis of different test indicators: Helicobacter pylori infection and the risk of colorectal cancer. Int J Colorectal Dis 2008; 23:875-882.
46. Zhang Y, Hoffmeister M, Weck MN, et al. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol 2012; 175:441-450.
47. Inoue I, Mukoubayashi C, Yoshimura N, et al. Elevated risk of colorectal adenoma with Helicobacter pylori-related chronic gastritis: a populationbased case-control study. Int J Cancer 2011; 129:2704-2711.
48. Hong SN, Lee SM, Kim JH, et al. Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. Dig Dis Sci 2012; 57:2184-2194.
49. Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011; 27:565-570.
50. Cammarota G, Branca G, Ardito F, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol 2010; 8:817-820.
51. Vitor JM, Vale FF. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol Med Microbiol 2011; 63:153-164.
52. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32:1069-1079.
53. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011; 45:960-966.
54. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2012 [Epub ahead of print]. Comprehensive data on H. pylori resistance patterns across European countries. 55. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34:1255-1268.
55. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011; 377:905-913.
56. Vaira D, Zullo A, Hassan C, et al. Sequential therapy for Helicobacter pylori eradication: the time is now! Therap Adv Gastroenterol 2009; 2:317-322.
57. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507-514.
58. Lee KJ, Inoue M, Otani T, et al. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006; 118:2315-2321.
59. Tashiro A, Sano M, Kinameri K, et al. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol 2006; 12:4873-4874.
60. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006; 4:709-716.
61. Kamada T, Hata J, Sugiu K, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther 2005; 21:1121-1126.
62. Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 2007; 42 (Suppl 17):21-27.
63. Di Mario F, Moussa AM, Caruana P, et al. 'Serological biopsy' in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection. Scand J Gastroenterol 2003; 38:1223-1227.
64. Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 2007; 8:15-22.
65. Leja M, Kupcinskas L, Funka K, et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci 2009; 54:2377-2384.
66. Oishi Y, Kiyohara Y, Kubo M, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006; 163:629-637.
67. Zhang X, Xue L, Xing L, et al. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. Int J Cancer 2011; 130:1614-1619.
68. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54:764-768.
69. Mizuno S, Miki I, Ishida T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci 2010; 55:3132-3137.
70. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9:245-253.
71. Brenner H, Rothenbacher D, Weck MN. Epidemiologic findings on serologically defined chronic atrophic gastritis strongly depend on the choice of the cutoff-value. Int J Cancer 2007; 121:2782-2786.
72. Kikuchi S, Kato M, Katsuyama T, et al. Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter 2006; 11:147-151.
73. Kitahara F, Kobayashi K, Sato T, et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44:693-697.
74. Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. Jpn J Cancer Res 1995; 86:1210-1215.
75. Mizuno S, Kobayashi M, Tomita S, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer 2009; 12:158-163.
76. Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008; 17:838-845.
77. Kang JM, Kim N, Yoo JY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter 2008; 13:146-156.
78. Shikata K, Ninomiya T, Yonemoto K, et al. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scand J Gastroenterol 2012; 47:669-675.
79. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010; 15 (Suppl 1):1-6.
80. Nasrollahzadeh D, Aghcheli K, Sotoudeh M, et al. Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis. PLoS One 2011; 6:e26957.
81. Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol 2012; 175:54-59.
82. McNulty CA, Lasseter G, Shaw I, et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 2012; 35:1221-1230.
83. Wex T, Venerito M, Kreutzer J, et al. Serological prevalence of Helicobacter pylori infection in Saxony-Anhalt, Germany, in 2010. Clin Vaccine Immunol 2011; 18:2109-2112.
84. Pandeya N, Whiteman DC. Prevalence and determinants of Helicobacter pylori sero-positivity in the Australian adult community. J Gastroenterol Hepatol 2011; 26:1283-1289.
85. Miendje D, Vanderpas J, Bontems P, et al. Marching cohort of Helicobacter pylori infection over two decades (1988-2007): combined effects of secular trend and population migration. Epidemiol Infect 2011; 139:572-580.
86. Smith SM, Moran AP, Duggan SP, et al. Tribbles 3: a novel regulator of TLR2-mediated signaling in response to Helicobacter pylori lipopolysaccharide. J Immunol 2011; 186:2462-2471.
87. Kumar PS, Brandt S, Madassery J, Backert S. Induction of TLR-2 and TLR-5 expression by Helicobacter pylori switches cagPAI-dependent signalling leading to the secretion of IL-8 and TNF-alpha. PLoS One 2011; 6:e19614.
88. Arnold IC, Dehzad N, Reuter S, et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 2011; 121:3088-3093.
89. Suzuki R, Shiota S, Yamaoka Y. Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori. Infect Genet Evol 2012; 12:203-213.
90. Rolig AS, Carter JE, Ottemann KM. Bacterial chemotaxis modulates host cell apoptosis to establish a T-helper cell, type 17 (Th17)-dominant immune response in Helicobacter pylori infection. Proc Natl Acad Sci U S A 2011; 108:19749-19754.
91. Katicic M, Filipec KT, Mrzljak A, et al. The decline in prevalence of H. pylori infection in Croatia affect significantly in incidence of esofago-gastro-duodenal (EGD) endoscopic findings. Helicobacter 2011; 16:105.
92. Zelickson MS, Bronder CM, Johnson BL, et al. Helicobacter pylori is not the predominant etiology for peptic ulcers requiring operation. Am Surg 2011; 77:1054-1060.
93. Kang JM, Kim N, Lee BH, et al. Risk factors for peptic ulcer bleeding in terms of Helicobacter pylori, NSAIDs, and antiplatelet agents. Scand J Gastroenterol 2011; 46:1295-1301.
94. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012; 61:646-664.
95. Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol 2012; 27:626-641.
96. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011; 171: 1929-1936.
97. Lan L, Yu J, Chen YL, et al. Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol 2011; 17:3242-3247.
98. Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol 2012; 47:129-135.
99. Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2011; 16 (Suppl 1):65-69.
100. Figura N, Franceschi F, Santucci A, et al. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010; 15 (Suppl 1):60-68.
101. Nweneka CV, Prentice AM. Helicobacter pylori infection and circulating ghrelin levels: a systematic review. BMC Gastroenterol 2011; 11:7.
102. Weigt J, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake. Curr Opin Clin Nutr Metab Care 2009; 12:522-525.
103. Akanuma M, Yanai A, Sakamoto K, et al. Influence of Helicobacter pylori eradication on the management of type 2 diabetes. Hepatogastroenterology 2012; 59:10.
104. Georges JL, Rupprecht HJ, Blankenberg S, et al. Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines. Am J Cardiol 2003; 92:515-521.
105. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115:1111-1119.
106. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010; 31:817-844.
107. Jeon CY, Haan MN, Cheng C, et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012; 35:520-525.
108. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the bloodbrain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003; 34:806-812.
109. Deretzi G, Kountouras J, Polyzos SA, et al. Gastrointestinal immune system and brain dialogue implicated in neuroinflammatory and neurodegenerative diseases. Curr Mol Med 2011; 11:696-707.
110. Mecocci P, Parnetti L, Reboldi GP, et al. Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias. Acta Neurol Scand 1991; 84:210-213.
111. Roubaud-Baudron C, Krolak-Salmon P, Quadrio I, et al. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiol Aging 2012; 33:1009.
112. Malaguarnera M, Ferri R, Bella R, et al. Homocysteine, vitamin B12 and folate in vascular dementia and in Alzheimer disease. Clin Chem Lab Med 2004; 42:1032-1035.
113. Kountouras J, Tsolaki M, Gavalas E, et al. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology 2006; 66:938-940.
114. Kountouras J, Boziki M, Gavalas E, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol 2009; 256:758-767.
115. Malaguarnera M, Bella R, Alagona G, et al. Helicobacter pylori and Alzheimer's disease: a possible link. Eur J Intern Med 2004; 15:381-386.
116. Shiota S, Murakami K, Yoshiiwa A, et al. The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. J Neurol 2011; 258:1460-1463.
117. Meucci G, Tatarella M, Vecchi M, et al. High prevalence of Helicobacter pylori infection in patients with colonic adenomas and carcinomas. J Clin Gastroenterol 1997; 25:605-607.
118. Shmuely H, Passaro D, Figer A, et al. Relationship between Helicobacter pylori CagA status and colorectal cancer. Am J Gastroenterol 2001; 96:3406-3410.
119. Siddheshwar RK, Muhammad KB, Gray JC, Kelly SB. Seroprevalence of Helicobacter pylori in patients with colorectal polyps and colorectal carcinoma. Am J Gastroenterol 2001; 96:84-88.
120. Konturek PC, Konturek SJ, Bielanski W, et al. Role of gastrin in gastric cancerogenesis in Helicobacter pylori infected humans. J Physiol Pharmacol 1999; 50:857-873.
121. Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastrin: active participant or bystander in gastric carcinogenesis? Nat Rev Cancer 2006; 6:936-946.
122. Niv Y. Gastrin and colorectal neoplasia: cause and effect. Digestion 2006; 74:40-41.
123. Zumkeller N, Brenner H, Zwahlen M, Rothenbacher D. Helicobacter pylori infection and colorectal cancer risk: a meta-analysis. Helicobacter 2006; 11:75-80.
124. Zhao YS, Wang F, Chang D, et al. Meta-analysis of different test indicators: Helicobacter pylori infection and the risk of colorectal cancer. Int J Colorectal Dis 2008; 23:875-882.
125. Zhang Y, Hoffmeister M, Weck MN, et al. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol 2012; 175:441-450.
126. Inoue I, Mukoubayashi C, Yoshimura N, et al. Elevated risk of colorectal adenoma with Helicobacter pylori-related chronic gastritis: a populationbased case-control study. Int J Cancer 2011; 129:2704-2711.
127. Hong SN, Lee SM, Kim JH, et al. Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. Dig Dis Sci 2012; 57:2184-2194.
128. Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011; 27:565-570.
129. Cammarota G, Branca G, Ardito F, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol 2010; 8:817-820.
130. Vitor JM, Vale FF. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol Med Microbiol 2011; 63:153-164.
131. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32:1069-1079.
132. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011; 45:960-966.
133. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2012 [Epub ahead of print]. Comprehensive data on H. pylori resistance patterns across European countries. 55. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34:1255-1268.
134. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011; 377:905-913.
135. Vaira D, Zullo A, Hassan C, et al. Sequential therapy for Helicobacter pylori eradication: the time is now! Therap Adv Gastroenterol 2009; 2:317-322.
136. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507-514.
137. Lee KJ, Inoue M, Otani T, et al. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006; 118:2315-2321.
138. Tashiro A, Sano M, Kinameri K, et al. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol 2006; 12:4873-4874.
139. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006; 4:709-716.
140. Kamada T, Hata J, Sugiu K, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther 2005; 21:1121-1126.
141. Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 2007; 42 (Suppl 17):21-27.
142. Di Mario F, Moussa AM, Caruana P, et al. 'Serological biopsy' in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection. Scand J Gastroenterol 2003; 38:1223-1227.
143. Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 2007; 8:15-22.
144. Leja M, Kupcinskas L, Funka K, et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci 2009; 54:2377-2384.
145. Oishi Y, Kiyohara Y, Kubo M, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006; 163:629-637.
146. Zhang X, Xue L, Xing L, et al. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. Int J Cancer 2011; 130:1614-1619.
147. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54:764-768.
148. Mizuno S, Miki I, Ishida T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci 2010; 55:3132-3137.
149. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9:245-253.
150. Brenner H, Rothenbacher D, Weck MN. Epidemiologic findings on serologically defined chronic atrophic gastritis strongly depend on the choice of the cutoff-value. Int J Cancer 2007; 121:2782-2786.
151. Kikuchi S, Kato M, Katsuyama T, et al. Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter 2006; 11:147-151.
152. Kitahara F, Kobayashi K, Sato T, et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44:693-697.
153. Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. Jpn J Cancer Res 1995; 86:1210-1215.
154. Mizuno S, Kobayashi M, Tomita S, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer 2009; 12:158-163.
155. Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008; 17:838-845.
156. Kang JM, Kim N, Yoo JY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter 2008; 13:146-156.
157. Shikata K, Ninomiya T, Yonemoto K, et al. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scand J Gastroenterol 2012; 47:669-675.
158. Nasrollahzadeh D, Aghcheli K, Sotoudeh M, et al. Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis. PLoS One 2011; 6:e26957.